Cargando…
Antroquinonol administration in animal preclinical studies for Alzheimer's disease (AD): A new avenue for modifying progression of AD pathophysiology
Despite the rise of Alzheimer's disease (AD) in an ageing population, no cure is currently available for this disorder. This study assessed the role of a natural compound, Antroquinonol, in modifying the progression of AD when administered at the start and/or before appearance of symptoms and w...
Autores principales: | Francesca, Fernandez, Caitlin, Aust, Sarah, Lye, Robyn, Griffiths Lyn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8892093/ https://www.ncbi.nlm.nih.gov/pubmed/35252893 http://dx.doi.org/10.1016/j.bbih.2022.100435 |
Ejemplares similares
-
Systemic Inflammation Causes Microglial Dysfunction With a Vascular AD phenotype
por: Bathini, Praveen, et al.
Publicado: (2022) -
Disease progression modelling from preclinical Alzheimer’s disease (AD) to AD dementia
por: Cho, Soo Hyun, et al.
Publicado: (2021) -
Antroquinonol A: Scalable Synthesis and Preclinical
Biology of a
Phase 2 Drug Candidate
por: Villaume, Matthew T., et al.
Publicado: (2015) -
Preparation and properties of rigid polyurethane foams added with graphene oxide-hollow glass microspheres hybrid
por: Liu, Dong, et al.
Publicado: (2021) -
Cell-free metabolic engineering enables selective biotransformation of fatty acids to value-added chemicals
por: Liu, Yushi, et al.
Publicado: (2022)